발행물
컨퍼런스
ISPOR Europe 2024
,
Cost-Effectiveness Analysis of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy As First-Line Therapy for Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer
A Validation of New Methods for Estimating Healthcare Costs Adjusted for End-of-Life Cost and Censoring
Lifetime Economic Burden of Hemophilia Using Phase-Based Costing and Survival Estimation Through Rolling Extrapolation
Comparative Effectiveness of Fenfluramine and Cannabidiol for Dravet Syndrome: A Network Meta-Analysis
ISPOR EUROPE 2024
Systematic Review of Patient Preferences Studies for Drugs and Medical Devices Using Discrete-Choice Experiments